{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2019-05-15&answer.dateOfAnswer=2019-05-22&min-answer.questionFirstAnswered.=2019-05-22T16%3A20%3A15.537Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-date=2019-05-15&answer.dateOfAnswer=2019-05-22&min-answer.questionFirstAnswered.=2019-05-22T16%3A20%3A15.537Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2019-05-15&answer.dateOfAnswer=2019-05-22&min-answer.questionFirstAnswered.=2019-05-22T16%3A20%3A15.537Z&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-date=2019-05-15&answer.dateOfAnswer=2019-05-22&min-answer.questionFirstAnswered.=2019-05-22T16%3A20%3A15.537Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2019-05-15&answer.dateOfAnswer=2019-05-22&min-answer.questionFirstAnswered.=2019-05-22T16%3A20%3A15.537Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2019-05-15&answer.dateOfAnswer=2019-05-22&min-answer.questionFirstAnswered.=2019-05-22T16%3A20%3A15.537Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1127334", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1127334/answer", "answerText" : {"_value" : "

As with all medicines in the United Kingdom, the Medicines and Healthcare products Regulatory Agency continuously monitors the safety of isotretinoin-containing medicines. This includes reports of suspected adverse drug reactions submitted by healthcare professionals, patients and carers through the Yellow Card scheme, as well as published and unpublished data. As new evidence on safety emerges it is carefully evaluated and, where appropriate, product information is updated and advice for prescribers and patients is issued.<\/p>

Specific assessments of possible psychiatric side effects associated with isotretinoin were considered by an Expert Working Group of the Commission on Human Medicines in 2005 and 2014. In addition, the risk of neuropsychiatric disorders was evaluated in a European review which was completed in 2018. This review concluded that the warnings in the product information for medicines containing isotretinoin regarding possible psychiatric adverse effects reflected what was known.<\/p>

Since 1998, warnings regarding the possible risk of developing depression and other psychiatric side effects have been included in the product information for Roaccutane and the generic versions of isotretinoin (the Summary of Product Characteristics for healthcare professionals and the patient information leaflet). The product information for isotretinoin warns that treatment may be associated with possible psychiatric side effects, that particular care needs to be taken in patients with a history of depression; and that all patients on isotretinoin should be monitored for signs of depression and referred for appropriate treatment if necessary. It also states that stopping isotretinoin may not lead to improvement and therefore further psychiatric or psychological evaluation may be necessary.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"} } , "answeringMemberConstituency" : {"_value" : "Thurrock"} , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"} , "dateOfAnswer" : {"_value" : "2019-05-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-22T16:42:43.927Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Isotretinoin: Side Effects"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential health risks and psychiatric side-effects of the drug Roaccutane.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1436", "label" : {"_value" : "Biography information for Paul Farrelly"} } , "tablingMemberConstituency" : {"_value" : "Newcastle-under-Lyme"} , "tablingMemberPrinted" : [{"_value" : "Paul Farrelly"} ], "uin" : "255661"} , {"_about" : "http://data.parliament.uk/resources/1127147", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1127147/answer", "answerText" : {"_value" : "

Government does not make assessments of the number of women in senior roles at UK energy companies, but alongside sponsoring the Hampton-Alexander Review on FTSE Women Leaders and promoting diversity in the energy sector, we support the work of POWERful Women which collates data on gender diversity in senior and middle management levels in the energy sector - which can be found at: http://powerfulwomen.org.uk/board-statistics-by-company/<\/a><\/p>

Strong progress has been made in that the representation of women on FTSE 100 boards has increased from 12.5% in 2011 to 31.6% in May 2019 and among executive directors has doubled from 5.5% to 10.3% in the same period.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4487", "label" : {"_value" : "Biography information for Kelly Tolhurst"} } , "answeringMemberConstituency" : {"_value" : "Rochester and Strood"} , "answeringMemberPrinted" : {"_value" : "Kelly Tolhurst"} , "dateOfAnswer" : {"_value" : "2019-05-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1127147/answer/previousversion/119452", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4487", "label" : {"_value" : "Biography information for Kelly Tolhurst"} } , "answeringMemberConstituency" : {"_value" : "Rochester and Strood"} , "answeringMemberPrinted" : {"_value" : "Kelly Tolhurst"} } , "questionFirstAnswered" : [{"_value" : "2019-05-22T16:20:15.537Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "201"} , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "date" : {"_value" : "2019-05-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Females: Directors"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what estimate his Department has made of the number of women in senior roles at UK energy companies.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/308", "label" : {"_value" : "Biography information for Mr Jim Cunningham"} } , "tablingMemberConstituency" : {"_value" : "Coventry South"} , "tablingMemberPrinted" : [{"_value" : "Mr Jim Cunningham"} ], "uin" : "255270"} , {"_about" : "http://data.parliament.uk/resources/1126962", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1126962/answer", "answerText" : {"_value" : "

No such assessment has been made, but the Government is considering options to ensure that our system of consumer protection provides a robust response to both local and national threats for the Consumer White Paper.<\/p>

<\/p>

The Government has endorsed the TrustMark scheme to reduce the number of rogue and incompetent builders; and to identify local traders who have undergone independent checks for both trade competence and good trading practice. This scheme gives consumers increased confidence and ability to choose registered businesses including builders who adhere to and maintain high standards.<\/p>

<\/p>

TrustMark is actively involved with Trading Standards to provide further protection to consumers affected by rogue builders.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4487", "label" : {"_value" : "Biography information for Kelly Tolhurst"} } , "answeringMemberConstituency" : {"_value" : "Rochester and Strood"} , "answeringMemberPrinted" : {"_value" : "Kelly Tolhurst"} , "dateOfAnswer" : {"_value" : "2019-05-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1126962/answer/previousversion/119032", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4487", "label" : {"_value" : "Biography information for Kelly Tolhurst"} } , "answeringMemberConstituency" : {"_value" : "Rochester and Strood"} , "answeringMemberPrinted" : {"_value" : "Kelly Tolhurst"} } , "questionFirstAnswered" : [{"_value" : "2019-05-22T16:20:22.1Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "201"} , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "date" : {"_value" : "2019-05-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Construction: Trading Standards"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment he has made of the effectiveness of Trading Standards in protecting consumers from rogue and incompetent builders in the construction industry.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4135", "label" : {"_value" : "Biography information for David Morris"} } , "tablingMemberConstituency" : {"_value" : "Morecambe and Lunesdale"} , "tablingMemberPrinted" : [{"_value" : "David Morris"} ], "uin" : "254821"} , {"_about" : "http://data.parliament.uk/resources/1126970", "AnsweringBody" : [{"_value" : "Ministry of Justice"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1126970/answer", "answerText" : {"_value" : "

The proportion of guilty pleas (where plea was known) has slowly been declining, from 74% in 2014 to 69% for white defendants, and from 61% in 2014 to 57% for BAME defendants in 2018.<\/p>

Data is only available for defendants dealt with at Crown Court (not all defendants) for indictable offences.<\/p>

The proportion of defendants who entered a guilty plea by ethnicity (2008 \u2013 2018) can be found in the Crown court data tool at the following link:<\/p>

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/802313/crown-court-tool-2018.xlsx<\/a><\/p>